SUPERNUS PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

SUPN$27.62+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Earnings

(in thousands, except share and per share data)

	Years Ended December 31,
	2023	2022	2021
Revenues
Net product sales	$573,933	$649,432	$567,504
Royalty and licensing revenues	33,588	17,806	12,271
Total revenues	607,521	667,238	579,775
Costs and expenses
Cost of goods sold (a)	83,779	87,221	75,061
Research and development	91,593	74,552	90,467
Selling, general and administrative	336,361	377,221	304,759
Amortization of intangible assets	82,385	82,630	29,989
Intangible asset impairment charges	20,189	—	—
Contingent consideration gain	(1,517)	(510)	(6,530)
Total costs and expenses	612,790	621,114	493,746
Operating earnings (loss)	(5,269)	46,124	86,029
Other income (expense)
Interest and other income, net	10,453	21,689	10,569
Interest expense	(2,415)	(7,070)	(23,423)
Total other income (expense)	8,038	14,619	(12,854)
Earnings before income taxes	2,769	60,743	73,175
Income tax expense	1,453	32	19,751
Net earnings	$1,316	$60,711	$53,424
Earnings per share
Basic	$0.02	$1.13	$1.01
Diluted	$0.02	$1.04	$0.98
Weighted-average shares outstanding
Basic	54,536,281	53,665,143	53,099,330
Diluted	55,506,828	61,679,800	54,356,744

(a) Excludes amortization of intangible assets.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.